FDA Approval of neffy (Epinephrine Nasal Spray) — First Needle-Free Anaphylaxis Treatment
Transparency & Verification
Verified from Official SourceAI Plain-Language Summary
Click "Generate" to create an AI-powered plain-language summary of this legislation.
Summary
On August 9, 2024, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) as the first needle-free emergency treatment for Type I allergic reactions, including anaphylaxis, in adults and children weighing 30 kg (66 lb.) or more. Unlike traditional epinephrine auto-injectors such as EpiPen, neffy is administered intranasally. A 1 mg pediatric dose for patients weighing 15 to less than 30 kg was approved on March 5, 2025.
Who This Bill Serves & Who's Backing It
Core Patient Populations
Patients who rely on timely access to emergency epinephrine.
Advocacy Groups Backing This Legislation
No advocacy organizations are currently tracked as backing this bill.Browse advocacy organizations →
Legislative Timeline
Votes & Legislative History
Public Access to Epinephrine
Public Access to Epinephrine Act
Allows authorized entities, including camps and sports venues, to acquire and stock epinephrine auto-injectors and nasal sprays for emergency use on individuals experiencing anaphylaxis, regardless of prior diagnosis.
Alex's Law
Student Self-Carry and Administration
Allows students to carry and self-administer life-saving medication on school premises, school buses, and during school activities with proper medical and parental authorization.
School Stocking Law
School Epinephrine and Albuterol Stocking
Permits schools to stock and administer emergency epinephrine and albuterol, requiring training for designated personnel and established emergency protocols.
While we strive for accuracy, information may change over time. Always double-check and verify against official sources before relying on it.